Lixte BiotechnologyLIXT
About: Lixte Biotechnology Holdings Inc is a biopharmaceutical company dedicated to improving patients' lives by developing a drug class called Protein Phosphatase 2A inhibitors. Its product pipeline is focused on inhibitors of protein phosphatase 2A, used in combination with cytotoxic agents and/or x-rays, immune checkpoint blockers, and other cancer therapies. The Company believes that inhibitors of protein phosphatases have therapeutic potential for a broad range of cancers. It focuses on the clinical development of a specific protein phosphatase inhibitor, referred to as LB-100, which has been shown to have clinical anti-cancer activity at doses that produce little or no toxicity.
Employees: 4
Fund manager confidence
Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)
17% more funds holding
Funds holding: 6 [Q2] → 7 (+1) [Q3]
1.65% more ownership
Funds ownership: 7.93% [Q2] → 9.58% (+1.65%) [Q3]
0% more repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 2
4% less capital invested
Capital invested by funds: $424K [Q2] → $409K (-$15K) [Q3]
Research analyst outlook
We haven’t received any recent analyst ratings for LIXT.
